文献速递免疫规划传染病防控与疫情报告

水痘疫苗III期试验中保护相关性与抗体浓度的关联分析

Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants.
PubMed 文献 · Vaccine · 2021-03-16

该研究对一项IIIb期随机对照试验(NCT00226499)进行事后分析,纳入5803名12-22月龄健康儿童,中位随访9.8年。结果显示水痘特异性抗体浓度与疫苗保护效力正相关,但未满足Prentice第四项保护相关性标准;抗体浓度越高,中重度突破性水痘发生概率越低。

要点

  • 接种1剂或2剂含水痘疫苗后6周,超过93.0%受种者水痘特异性抗体血清阳性。
  • 水痘特异性抗体浓度与疫苗效力呈正相关,但未满足Prentice第四项标准。

核心结论

  • 水痘特异性抗体浓度与保护效力呈正相关,是保护的良好预测指标。
  • 由于血清阴性受种者仍预测有阳性疫苗效力,未满足Prentice第四项保护相关性标准。

研究设计与样本

  • 受种者按3:3:1随机分为1剂水痘疫苗组、2剂麻疹-腮腺炎-风疹-水痘疫苗组和2剂麻疹-腮腺炎-风疹疫苗对照组,间隔6周接种。
  • 试验纳入5803名参与者,效力队列5289人(1剂组2266、2剂组2279、对照组744),免疫原性队列5235人(各组分别为2248、2245、742)。
  • 中位随访9.8年,试验于2016年结束,采用Cox比例风险模型及Dunning加速失效时间模型分析。

主要发现

  • 接种1剂或2剂含水痘疫苗后6周,超过93.0%受种者水痘特异性抗体血清阳性。
  • 估计疫苗效力与抗体浓度呈正相关。

关键数值与推荐

  • Prentice第四项保护相关性标准未满足,因模型预测血清阴性受种者仍有阳性疫苗效力。

临床怎么用

  • 水痘特异性抗体浓度可用于预测个体及群体水平的水痘保护水平。
  • 抗体浓度较高(≥血清阳性界值2倍)提示中重度突破性水痘长期风险较低。

局限性

  • 本研究为事后分析,原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Varicella vaccination confers high and long-lasting protection against chickenpox and induces robust immune responses, but an absolute correlate of protection (CoP) against varicella has not been established. This study models the relationship between varicella humoral response and protection against varicella. METHODS: This was a post-hoc analysis of data from a Phase IIIb, multicenter, randomized trial (NCT00226499) conducted in ten varicella-endemic European countries. Healthy children aged 12-22 months were randomized 3:3:1 to receive one dose of measles-mumps-rubella and one dose of varicella vaccine (one-dose group) or two doses of measles-mumps-rubella-varicella vaccine (two-dose group) or two doses of measles-mumps-rubella vaccine (control group) six weeks apart. The study remained observer-blind until completion, except in countries with obligatory additional immunizations. The objective was to correlate varicella-specific antibody concentrations with protection against varicella and probability of varicella breakthrough, using Cox proportional hazards and Dunning and accelerated failure time statistical models. The analysis was guided by the Prentice framework to explore a CoP against varicella. RESULTS: The trial included 5803 participants, 5289 in the efficacy (2266: one-dose group, 2279: two-dose group and 744: control group) and 5235 (2248, 2245 and 742 in the same groups) in the immunogenicity cohort. The trial ended in 2016 with a median follow-up time of 9.8 years. Six weeks after vaccination with one- or two-dose varicella-containing vaccine, more than 93.0% of vaccinees were seropositive for varicella-specific antibodies. Estimated vaccine efficacy correlated positively with antibody concentrations. The fourth Prentice CoP criterion was not met, due to predicted positive vaccine efficacy in seronegative participants. Further modelling showed decreased probability of moderate to severe varicella breakthrough with increasing varicella-specific antibody concentrations (ten-year probability <0.1 for antibody concentrations ≥2-fold above the seropositivity cut-off). CONCLUSIONS: Varicella-specific antibody concentrations are a good predictor of protection, given their inverse correlation with varicella occurrence. CLINICAL TRIAL: NCT00226499.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Habib MA, Prymula R, Carryn S, et al. Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants. Vaccine. 2021. PMID: 33736915. doi:10.1016/j.vaccine.2021.02.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。